Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Primary biliary cirrhosis (PBC) is a chronic cholestatic disease characterized by the presence of antimitochondrial antibodies (AMA). PBC-specific antinuclear antibodies (ANA) have been characterized and associated with disease progression and outcome. We evaluated the clinical significance of the presence and serial changes in titers of AMA, PBC-specific ANA (anti-gp210, anti-sp100) and anti-chromatin antibodies. Over a median (IQR) period of 35 (36) months, 512 specimens were collected from 110 patients. Autoantibodies were detected by commercial ELISAs (INOVA Diagnostics). Biochemical, clinical, and histological status were included at initial presentation and during follow-up visits. The Mayo risk score was calculated as a prognostic index at each time point. Liver biopsy findings were classified according to Ludwig's classification and biochemical response to ursodeoxycholic acid was evaluated according to Pares. At baseline, AMA IgG and IgA, anti-gp210 IgG, anti-sp100 IgG and anti-chromatin IgG were detected in 92/110 (83.6%), 57/110 (51.8%), 5/110 (4.5%), 14/110 (12.7%), and 0/110 (0%) patients, respectively. Positivity for all autoantibodies apart from anti-chromatin, at baseline visit (n = 110 patients), in all tested sera (n = 512) as well as increased autoantibodies titers during follow-up were associated with biochemically and/or histologically advanced disease. A decrease of anti-sp100 titers but not of anti-gp210 titers during follow-up was associated with improvement of Mayo risk score (p = 0.025) and response to ursodeoxycholic acid (p = 0.016). These results suggest that detection of AMA and PBC-specific ANA was correlated with disease severity. Serial changes of anti-sp100 titers and not of anti-gp210 titers might prove useful for monitoring the disease course and treatment outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Simplified criteria for the diagnosis of autoimmune hepatitis
Hennes, E. M., Zeniya, M., Czaja, A. J., Parés, A., Dalekos, G. N., Krawitt, E. L., Bittencourt, P. L., Porta, G., Boberg, K. M., Hofer, H., et al. (2008) · Hepatology · doi:10.1002/hep.22322 · Cited by 1,901
Self-citationPrognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816 · cited 1×
“The Mayo risk score was calculated as a prognostic index in all patients at each time point [35,36].”
MethodParés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756 · cited 1×
“Although baseline anti-gp210 or anti-sp100 positivity were not significantly associated with response to UDCA during follow-up, only patients (n1⁄4 64) who fulfilled treatment response according to Pares criteria [38] significantly associated with a decrease of anti-sp100 titers [ 0.”
MethodStaging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Nakamura, M., Kondo, H., Mori, T., Komori, A., Matsuyama, M., Ito, M., Takii, Y., Koyabu, M., Yokoyama, T., Migita, K., et al. (2007) · Hepatology · doi:10.1002/hep.21472 · Cited by 365
Self-citationInvernizzi, P., Crosignani, A., Battezzati, P. M., Covini, G., De Valle, G., Larghi, A., Zuin, M., & Podda, M. (1997) · Hepatology · doi:10.1002/hep.510250507 · Cited by 293
Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis
Muratori, P., Muratori, L., Ferrari, R., Cassani, F., Bianchi, G., Lenzi, M., Rodrigo, L., Linares, A., Fuentes, D., & Bianchi, F. B. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07257.x · Cited by 204 · cited 11×
“To define the PBC-specific ANA pattern (multiple nuclear dots, MND and rim like membran- ous, RLM) all sera were also evaluated with IIF on HEp-2 cells (INOVA Diagnostics Inc., San Diego, CA) using standard protocols.”
BackgroundInfluentialCorrelation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis
Wesierska-Gadek, J., Penner, E., Battezzati, P. M., Selmi, C., Zuin, M., Hitchman, E., Worman, H. J., Gershwin, E. M., Podda, M., & Invernizzi, P. (2006) · Hepatology · doi:10.1002/hep.21172 · Cited by 177
Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis
Springer, J., Cauch-Dudek, K., O'Rourke, K., Wanless, I. R., & Heathcote, E. J. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.00770.x · Cited by 141 · cited 1×
“Although AMA are detected in more than 90% of PBC patients [1,5,6] often long before the disease is clinically overt [3,7], they seem to lack prognostic value and do not define clinically different subpopulations [8], nor change significantly during the disease progression [9].”
BackgroundLiu, H., Norman, G. L., Shums, Z., Worman, H. J., Krawitt, E. L., Bizzaro, N., Vergani, D., Bogdanos, D. P., Dalekos, G. N., Milkiewicz, P., et al. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2010.09.005 · Cited by 130
Self-citation
Cited by
You, H., Ma, X., Efe, C., Wang, G., Jeong, S.-H., Abe, K., Duan, W., Chen, S., Kong, Y., Zhang, D., et al. (2022) · Hepatology International · doi:10.1007/s12072-021-10276-6 · Cited by 133
Wang, L., Han, Q., Chen, H., Wang, K., Shan, G.-L., Kong, F., Yang, Y.-J., Li, Y.-Z., Zhang, X., Dong, F., et al. (2014) · Stem Cells and Development · doi:10.1089/scd.2013.0500 · Cited by 89
Role of autoantibodies in the clinical management of primary biliary cholangitis
Rigopoulou, E. I., & Bogdanos, D. P. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i12.1795 · Cited by 30
Metadata
- Authors
- Gatselis, N. K., Zachou, K., Norman, G. L., Gabeta, S., Papamichalis, P., Koukoulis, G. K., & Dalekos, G. N.
- Venue
- Autoimmunity
- Publisher
- Informa UK Limited
- Published
- 2013-06-19
- Volume
- 46
- Issue
- 7
- Pages
- 471-479
- ISSN
- 0891-6934 (ISSN-L)
- 1607-842X
- OpenAlex
- W1995764546
- Cited by
- 64
- References
- 14
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. https://app.cochat.ai/papers/10.3109/08916934.2013.801461
- The paper
- Gatselis, N. K., Zachou, K., Norman, G. L., Gabeta, S., Papamichalis, P., Koukoulis, G. K., & Dalekos, G. N. (2013). Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. Autoimmunity. https://doi.org/10.3109/08916934.2013.801461
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.